Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2/3 2Phase 2 2Phase NA 1Phase EARLY_PHASE1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 2Prostate Adenocarcinoma 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Interventional × Salicylic Acid × Clear all
NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NRG Oncology

Phase 3 Active not recruiting
2,753 enrolled
Genitourinary

Prostatic Neoplasms

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT03678025 2025-09-11

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

SWOG Cancer Research Network

Phase 3 Recruiting
1,273 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡